Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SFDA Tightens TCM Injection Regulations

This article was originally published in PharmAsia News

Executive Summary

China's State Food and Drug Administration recently released the basic technology requirements for traditional Chinese medicine and natural injection to tackle problems in TCM injection such as complicated chemical ingredients, poor preparation technology, shoddy standards, and undeterminate clinical effects. The new regulation requires TCM and natural product injection to identify their ingredients, with single-ingredient TCM injections attaining a purity level of 90 percent. It also seeks to regulate injections with altered route of administration or dosage and better guidelines for generic drugs. Besides imposing more control on non-clinical study and clinical trials, SFDA proposes a surveillance system on adverse drug reactions. Industry observers believe that the stricter regulations will raise TCM production safety and efficacy. (Click here for more
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

SC065944

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel